Novo Nordisk and Sanofi urged a federal appeals court in Philadelphia to reverse a district judge’s ruling that their denials on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation

Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report